688553 匯宇製藥
按盤價 
12.320 +1.230 (+11.091%) | 2026/06 - 中期 人民幣(K¥) | 與去年同期 比較 | 2025/12 人民幣(K¥) | 2024/12 人民幣(K¥) | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | ||
| 營業總收入 | 551,856 | 21.79% | 998,145 | 1,094,382 | 927,075 | 1,493,268 | |
| 減：營業總成本 | 471,782 | 9.75% | 923,789 | 1,006,585 | 873,712 | 1,304,312 | |
| 其中:營業成本 | 128,336 | 37.52% | 203,595 | 181,511 | 130,447 | 176,182 | |
| 財務費用 | (26,566) | -17.38% | (48,771) | (22,120) | (41,802) | (46,899) | |
| 資產減值損失 | (4,293) | -4,287.78% | (5,406) | (14,814) | (2,307) | (3,933) | |
| 公允價值變動收益 | (30,420) | -79.21% | (167,004) | 239,856 | 6,440 | 2,327 | |
| 投資收益 | (7,375) | -343.43% | 477 | 13,815 | 34,183 | 42,894 | |
| 其中：對聯營企業和合營企業的投資收益 | 264 | -18.97% | (752) | (2,687) | 307 | 1,471 | |
| 營業利潤 | 48,022 | -145.16% | (66,225) | 348,432 | 124,368 | 235,448 | |
| 利潤總額 | 49,322 | -146.97% | (64,313) | 349,699 | 132,154 | 238,391 | |
| 減：所得稅費用 | (7,741) | -63.84% | (33,765) | 33,802 | (7,180) | (10,599) | |
| 淨利潤 | 57,064 | -168.26% | (30,548) | 315,897 | 139,335 | 248,991 | |
| 減：非控股權益 | (585) | -79.66% | (5,586) | (9,493) | (451) | -- | |
| 股東淨利潤 | 57,649 | -171.42% | (24,961) | 325,390 | 139,786 | 248,991 | |
市場價值指標 | |||||||
| 每股收益 (元) * | 0.090 | -147.37% | -0.060 | 0.770 | 0.330 | 0.590 | |
| 每股派息 (元) * | -- | -- | 0.200 | 0.463 | 0.213 | 0.235 | |
| 每股淨資產 (元) * | 5.959 | -31.79% | 8.872 | 9.393 | 8.901 | 8.777 | |
| 審計意見 # | -- | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 即時報價更新時間為 21/09/2026 16:30 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
